Table of Content

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Chronic Myelogenous Leukemia Therapeutics Market, by Region

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing number of diagnostic tests and predictive markers
5.1.1.2. Growing prevalence of chronic myelogenous leukemia
5.1.1.3. Rising awareness programs regarding chronic myeloid leukemia
5.1.2. Restraints
5.1.2.1. High cost of chronic myeloid leukemia treatment drugs
5.1.3. Opportunities
5.1.3.1. Increasing research and development activities for chronic myeloid leukemia treatment
5.1.3.2. Rising approval of drugs for treating chronic myelogenous leukemia
5.1.4. Challenges
5.1.4.1. Side effects and adverse reactions of chronic myeloid leukemia treatment
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Chronic Myelogenous Leukemia Therapeutics Market, by Treatment Type
6.1. Introduction
6.2. Biologic Therapy
6.3. Chemotherapy
6.4. Targeted Therapy
6.5.1. Tyrosine Kinase Inhibitors
6.5.2.1. Antimetabolites
6.5.2.2. Asciminib
6.5.2.3. Bosutinib
6.5.2.4. Dasatinib
6.5.2.5. Nilotinib
6.5.2.6. Ponatinib

7. Chronic Myelogenous Leukemia Therapeutics Market, by Distribution Channel
7.1. Introduction
7.2. Hospital Pharmacies
7.3. Online Pharmacies
7.4. Retail Pharmacies

8. Americas Chronic Myelogenous Leukemia Therapeutics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Chronic Myelogenous Leukemia Therapeutics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Chronic Myelogenous Leukemia Therapeutics Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. Abbvie Inc.
12.1.2. Amneal Pharmaceuticals LLC
12.1.3. Bristol Myers Squibb Company
12.1.4. F. Hoffmann La Roche Ltd.
12.1.5. Ilyang Pharmaceutical Co. Ltd.
12.1.6. Incyte Corporation
12.1.7. Innovent Biologics Inc.
12.1.8. Lupin Ltd.
12.1.9. Merck KGaA
12.1.10. Novartis AG
12.1.11. Pfizer Inc.
12.1.12. Sanofi S.A.
12.1.13. Sun Pharmaceutical Industries Ltd.
12.1.14. Takeda Pharmaceutical Co. Ltd.
12.1.15. Teva Pharmaceutical Industries Ltd.
12.1.16. Viatris Inc.
12.2. Key Product Portfolio

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing



List of Figures

FIGURE 1. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET DYNAMICS
FIGURE 7. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 8. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 10. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018–2023
TABLE 3. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 6. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 10. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 12. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ASCIMINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BOSUTINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DASATINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY NILOTINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PONATINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 19. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 36. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 37. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 38. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 40. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 41. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 42. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. AUSTRALIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 54. AUSTRALIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. CHINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 58. CHINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 59. CHINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 60. CHINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. INDIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 62. INDIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 63. INDIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 64. INDIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. INDONESIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 66. INDONESIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. JAPAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 70. JAPAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 71. JAPAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 72. JAPAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. MALAYSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 74. MALAYSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. PHILIPPINES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 78. PHILIPPINES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. SINGAPORE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 82. SINGAPORE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 83. SINGAPORE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. SOUTH KOREA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 86. SOUTH KOREA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 87. SOUTH KOREA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. TAIWAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 90. TAIWAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 91. TAIWAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. THAILAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 94. THAILAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 95. THAILAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 96. THAILAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. VIETNAM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 98. VIETNAM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 99. VIETNAM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 106. DENMARK CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. DENMARK CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 108. DENMARK CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 109. DENMARK CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. EGYPT CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 111. EGYPT CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 112. EGYPT CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 113. EGYPT CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. FINLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 115. FINLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 116. FINLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 117. FINLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 119. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 120. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 121. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 123. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 124. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 125. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. ISRAEL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 127. ISRAEL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 128. ISRAEL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 131. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 132. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 133. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. NORWAY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 143. NORWAY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 144. NORWAY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 145. NORWAY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. POLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. POLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 148. POLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 149. POLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. QATAR CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 151. QATAR CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 152. QATAR CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 153. QATAR CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 167. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 168. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 169. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. SWEDEN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. SWITZERLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 175. SWITZERLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. TURKEY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 179. TURKEY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 180. TURKEY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 181. TURKEY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 191. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 192. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET LICENSE & PRICING